Literature DB >> 16267621

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.

Lucy E Hudsmith1, Steffen E Petersen, Jane M Francis, Matthew D Robson, Hugh Watkins, Stefan Neubauer.   

Abstract

A 27 year old female with Noonan syndrome and hypertrophic cardiomyopathy underwent cardiovascular magnetic resonance imaging. These images showed asymmetrical septal hypertrophy with maximal left ventricular end-diastolic wall thickness of 25 mm. Following administration of gadolinium, areas of hyperenhancement were seen in the anterior, anteroseptal and lateral walls. This is the first report of focal gadolinium hyperenhancement in hypertrophic cardiomyopathy due to Noonan syndrome and suggests that myocardial fibrosis can be imaged by MR hyperenhancement as seen previously in sarcomeric hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267621     DOI: 10.1007/s10554-005-9034-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  5 in total

1.  Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  James M Wilson; Rollo P Villareal; Ramesh Hariharan; Ali Massumi; Raja Muthupillai; Scott D Flamm
Journal:  Tex Heart Inst J       Date:  2002

2.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  James C C Moon; Emma Reed; Mary N Sheppard; Andrew G Elkington; Siew Yen Ho; Margaret Burke; Mario Petrou; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

3.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

Authors:  James C C Moon; William J McKenna; Jane A McCrohon; Perry M Elliott; Gillian C Smith; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

4.  Myocardial disarray in Noonan syndrome.

Authors:  M Burch; J M Mann; M Sharland; E A Shinebourne; M A Patton; W J McKenna
Journal:  Br Heart J       Date:  1992-12

5.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  Lubna Choudhury; Heiko Mahrholdt; Anja Wagner; Kelly M Choi; Michael D Elliott; Francis J Klocke; Robert O Bonow; Robert M Judd; Raymond J Kim
Journal:  J Am Coll Cardiol       Date:  2002-12-18       Impact factor: 24.094

  5 in total
  6 in total

1.  Influence of a constitutive increase in myofilament Ca(2+)-sensitivity on Ca(2+)-fluxes and contraction of mouse heart ventricular myocytes.

Authors:  Jose L Puglisi; Paul H Goldspink; Aldrin V Gomes; Megan S Utter; Donald M Bers; R John Solaro
Journal:  Arch Biochem Biophys       Date:  2014-01-27       Impact factor: 4.013

2.  Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 2: Rare phenotypes.

Authors:  Ailbhe C O'Neill; Shaunagh McDermott; Carole A Ridge; David Keane; Jonathan D Dodd
Journal:  World J Cardiol       Date:  2012-05-26

3.  Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy.

Authors:  Emanuel Kaltenecker; Julia Schleihauf; Christian Meierhofer; Nerejda Shehu; Naira Mkrtchyan; Alfred Hager; Andreas Kühn; Julie Cleuziou; Karin Klingel; Heide Seidel; Martin Zenker; Peter Ewert; Gabriele Hessling; Cordula M Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

4.  Uncharted waters: rare and unclassified cardiomyopathies characterized on cardiac magnetic resonance imaging.

Authors:  Ailbhe C O'Neill; Shaunagh McDermott; Carole A Ridge; Kenneth McDonald; David Keane; Jonathan D Dodd
Journal:  Insights Imaging       Date:  2010-10-19

5.  Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.

Authors:  Anna B Meier; Sarala Raj Murthi; Hilansi Rawat; Christopher N Toepfer; Gianluca Santamaria; Manuel Schmid; Elisa Mastantuono; Thomas Schwarzmayr; Riccardo Berutti; Julie Cleuziou; Peter Ewert; Agnes Görlach; Karin Klingel; Karl-Ludwig Laugwitz; Christine E Seidman; Jonathan G Seidman; Alessandra Moretti; Cordula M Wolf
Journal:  iScience       Date:  2021-12-09

6.  The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis.

Authors:  Ariella Zehender; Jingang Huang; Andrea-Hermina Györfi; Alexandru-Emil Matei; Thuong Trinh-Minh; Xiaohan Xu; Yi-Nan Li; Chih-Wei Chen; Jianping Lin; Clara Dees; Christian Beyer; Kolja Gelse; Zhong-Yin Zhang; Christina Bergmann; Andreas Ramming; Walter Birchmeier; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Nat Commun       Date:  2018-08-14       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.